A Plain-Language Tirzepatide Information Sheet

How tirzepatide works — and why the dual mechanism matters

Most GLP-1 medicines act on a single receptor. Tirzepatide adds a second: the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both receptors are involved in appetite signalling and blood-sugar regulation, and activating them together slows the rate at which the stomach empties, increases the feeling of fullness after eating, and reduces overall calorie intake over time. The clinical question for many people is whether that second pathway makes a meaningful difference to outcomes.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and followed them for 72 weeks. At the 15 mg maintenance dose, average body-weight reduction was around 20–21%. A subsequent head-to-head study, SURMOUNT-5, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same duration. Those figures do not tell you what will happen for any one person (biology varies) but they are the evidence base the prescribers and NICE used to assess the medicine's place in treatment. You can read how NICE weighed that evidence in technology appraisal TA1026.

Understanding the mechanism also explains the dosing structure. The 2.5 mg starting dose is not a treatment dose in the therapeutic sense; its job is to let your body settle into the medicine before the dose is gradually raised. Nausea is almost always worse when the dose increases quickly, so the titration schedule exists for comfort as much as efficacy. Your prescriber decides the pace, not you.

Who this medicine is licensed for, and what changes that picture

The UK licence covers adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present. Qualifying conditions include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea, and cardiovascular disease, among others. BMI alone never guarantees that tirzepatide is the right choice; a prescriber weighs up your whole picture, including any medicines you already take and conditions that might make certain treatments unsuitable.

NICE's recommendation is more specific than the licence. TA1026, updated in September 2025, recommends tirzepatide on the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold is 2.5 kg/m² lower throughout. If the medicine does not produce at least 5% weight loss after six months at the highest tolerated dose, continuing is reviewed.

A separate private route exists for people who do not meet NHS thresholds or who prefer not to wait. The Mounjaro overview page explains how both routes work. Tirzepatide is not recommended for people who are pregnant, breastfeeding, or actively trying to conceive, and it is not licensed for use in anyone under 18. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication; other conditions require discussion with the prescriber before starting.

Side effects: what to expect and what to act on quickly

The most common side effects are gastrointestinal. Nausea is the one patients mention most, followed by diarrhoea, constipation, indigestion, and bloating. These tend to peak in the first few days after a dose increase and ease off as the weeks pass. Eating smaller portions, avoiding rich or fatty meals, and staying well hydrated all help. Fatigue, headache, and mild dizziness also appear in the reported side-effect data. Injection-site redness or tenderness is generally short-lived.

Some side effects warrant prompt medical attention rather than watchful waiting. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines: severe stomach pain that does not ease and may spread to the back, with or without vomiting, is the signal to contact a doctor or call 111 the same day. Gallbladder problems, symptoms of dehydration after prolonged vomiting or diarrhoea, and any sign of a serious allergic reaction are also reasons to seek help without delay. The NHS tirzepatide medicines page lists side effects clearly and is a reliable first reference. Side effects can also be reported directly to the MHRA at the Yellow Card scheme.

Women using the oral contraceptive pill should be aware that tirzepatide's effect on gastric emptying can reduce pill absorption. Adding a non-oral form of contraception for the first four weeks of treatment and for four weeks after each dose increase is the current MHRA and NHS guidance. The same absorption caution applies to oral HRT; transdermal forms such as patches or gels are worth discussing with your GP if this applies to you. For a fuller side-effect reference, our Mounjaro information page sets out the patient-level detail.

The practical shape of tirzepatide treatment, and what to weigh up

Tirzepatide comes as a pre-filled KwikPen; you inject once a week into the abdomen, thigh, or upper arm, rotating the site each time. The pen stays in the fridge between uses, at 2–8°C. Storage windows outside the fridge exist but vary, and the Mounjaro patient information PDF is the place to check exact figures, not online estimates. If you want to understand the full directions for use and safety information as approved by the medicines regulator, you can also read the Mounjaro prescribing information, which covers the clinical detail behind dosing and administration.

If you order through a regulated private pharmacy, the pen arrives via tracked DPD delivery in plain, unmarked packaging, no indication of contents on the outside. That is worth knowing if discretion matters to you.

For people considering costs alongside clinical factors, the Mounjaro pricing page explains what a legitimate private prescription includes and why the range of prices advertised online varies as much as it does. A single transparent price covering the consultation, prescription, treatment and next-working-day delivery is the model that avoids the hidden charges that make headline figures misleading.

The decision about whether to start tirzepatide, and at what point in a wider weight-management plan, is genuinely a clinical one. It is not simply a question of whether your BMI qualifies; it is about whether the medicine fits your health situation, your other treatments, and your goals. Before or after your consultation, you may find it helpful to read the Mounjaro information leaflet, which sets out in plain terms what the medicine is, how to use it, and what to watch for. If you want to explore whether it might be suitable, speaking to our prescribers is the starting point, and the consultation is free. For broader context on how tirzepatide sits within the wider landscape of weight-loss treatment, the weight-loss treatments overview is a useful read before you decide.